Tag

Arexvy

All articles tagged with #arexvy

health2 years ago•2 min saved

GSK's RSV Vaccine Demonstrates Promising Protection for Adults 50-59

GlaxoSmithKline's RSV vaccine, Arexvy, has shown potential in protecting adults aged 50 to 59 from respiratory syncytial virus (RSV) in a late-stage clinical trial. The vaccine elicited an immune response in this age group without any adverse effects, and the safety data was consistent with that of adults aged 60 and above. GSK plans to submit the final trial results for regulatory review and expects a decision on expanding the vaccine's label in 2024. Currently, Pfizer is the only other company with an approved RSV vaccine, but it is unclear if they will present data for adults aged 50 to 59. RSV causes thousands of hospitalizations and deaths among older Americans each year.

via CNBC|

#adults-50-to-59 #arexvy #glaxosmithkline

healthcare2 years ago•3 min saved

Overcoming Vaccine Hesitancy in Patients.

The FDA has approved Arexvy, a vaccine against respiratory syncytial virus (RSV) for adults aged 60 years or older. RSV infection led to more than 100,000 hospitalizations and 7700 deaths in older adults in the United States in 2019. Arexvy reduced severe RSV disease by 94% and RSV-related acute respiratory infections by 71%. However, patient hesitancy may be a challenge in incorporating this new vaccine into practice. It's important for healthcare providers to educate colleagues, staff, and patients about preventing serious illness caused by RSV.

via Medscape|

#arexvy #healthcare #older-adults

health2 years ago•4 min saved

RSV vaccine approved and in development for winter season.

The FDA has approved a vaccine called Arexvy for adults 60 and older against RSV, a common virus that can cause severe respiratory illness in young children and older adults. The vaccine is expected to be available in the fall pending a recommendation from the CDC. The vaccine was found to be 83% effective at preventing lower respiratory tract disease caused by RSV and 94% effective at preventing severe disease. People should still receive the annual flu vaccine and follow CDC guidance on when to receive another Covid-19 booster. The vaccine is not yet approved for young children, but Pfizer is developing an RSV vaccine for pregnant women to convey protection to infants.

via CNN|

#arexvy #cdc #health

health2 years ago•2 min saved

RSV Vaccine Approved and Expected to Arrive Soon in Hagerstown

The US FDA has approved the first vaccine for respiratory syncytial virus (RSV), a common cold-like illness that can cause severe respiratory illness in infants and older adults. The vaccine, called Arexvy, will be used to protect adults aged 60 and above, one of the two most susceptible populations to the virus. The other population is infants and younger children, for whom a vaccine is still being developed. The first shipments of the Arexvy vaccine are expected to arrive in Washington County later this month. Other RSV vaccines and treatments are also under review by regulatory agencies.

via Herald-Mail Media|

#arexvy #health #infants

health2 years ago•5 min saved

FDA approves first-ever RSV vaccine for older adults, a huge milestone.

The FDA has approved the first vaccine that protects against respiratory syncytial virus (RSV), a virus that causes cold symptoms and can lead to severe lung inflammation or infection in very young and very old people. The vaccine, known as Arexvy, was approved for adults 60 and over and reduced the risk of lower respiratory tract illness in adults over 60 by nearly 83 percent, and the risk of severe illness by 94 percent. The vaccine is highly effective and has generally mild side effects, and the FDA will monitor for severe side effects. RSV vaccines could save hundreds of thousands of lives each year on a global scale.

via Vox.com|

#arexvy #fda #health

health2 years ago•3 min saved

FDA Approves First-Ever RSV Vaccine for Older Adults

The FDA has approved the first respiratory syncytial virus (RSV) vaccine, Arexvy, for use in individuals 60 years of age and older. RSV is a highly contagious virus that causes infections of the lungs and breathing passages, and is a common cause of lower respiratory tract disease (LRTD) in older adults. Arexvy significantly reduced the risk of developing RSV-associated LRTD by 82.6% and reduced the risk of developing severe RSV-associated LRTD by 94.1%. The vaccine's safety and effectiveness is based on an ongoing, randomized, placebo-controlled clinical study.

via FDA.gov|

#arexvy #fda #health